Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Artificial pancreas system reduces risk of nocturnal hypoglycemia

An article recently published in The Lancet reports that using an artificial pancreas system overnight can significantly reduce the risk of nocturnal hypoglycemia in children and adolescents with type 1 diabetes. Moreover, the first clinical trial of an artificial pancreas system delivering both insulin and glucagon has shown that this system can prevent development of hypoglycemia.

19 Jun 2010

Gladstone Institute researcher to receive Kyoto Prize in Advanced Technology

The non-profit Inamori Foundation (President: Dr. Kazuo Inamori) today announced that Dr. Shinya Yamanaka will receive its 26th annual Kyoto Prize in Advanced Technology, which for 2010 focuses on the fields of Biotechnology and Medical Technology. Dr. Yamanaka, 47, will receive the award for his pioneering work in developing a technology to generate pluripotent stem cells that does not require the use of human embryos.

18 Jun 2010

InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting

InteKrin Therapeutics Inc. announced today it will present 6 month Phase 2b clinical data for edema in diabetic patients showing differentiation for INT131, a Selective PPAR-gamma Modulator (SPPARM), from Actos® pioglitazone, at the American Diabetes Association annual meeting in Orlando, FL, Monday, June 28, 2010 at 2:45 pm EDT during the "Update on BARI 2D --Treatment of Insulin Resistance" session.

18 Jun 2010

Physical fitness reduces metabolic risk in college students

Staying in shape may bolster the metabolic profiles of college students, even in those with higher than desirable body fat percentages. In an epidemiological study, researchers at the Friedman School of Nutrition Science and Policy at Tufts University found an association between physical fitness, body fat percentage and certain metabolic risk factors that are precursors to cardiovascular disease and Type 2 diabetes.

18 Jun 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.

18 Jun 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.

18 Jun 2010

Roche implements risk mitigation plan in taspoglutide Phase III programme

Ipsen, a global biopharmaceutical group, today announced that its partner Roche today announced the implementation of a risk mitigation plan in the taspoglutide Phase III programme. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.

18 Jun 2010

Research identifies early biomarker for insulin resistance, glucose intolerance in nondiabetic population

Metabolon, Inc., the leader in metabolomics-based biomarker discovery and analysis, today announced the publication of research that identified a novel, early biomarker for insulin resistance and glucose intolerance in a nondiabetic population.

17 Jun 2010

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

17 Jun 2010

Biological mechanism associated with remission during pregnancy

During pregnancy, many women experience remission of autoimmune diseases like multiple sclerosis and uveitis. Now, scientists have described a biological mechanism responsible for changes in the immune system that helps to explain the remission.

17 Jun 2010

Teva exercises option to invest additional $11.9M in Andromeda Biotech

Andromeda Biotech Ltd. announces that Teva Pharmaceutical Industries Ltd. decided to exercise its option to invest in Andromeda Biotech Ltd. at a company per-money valuation of 170 million US dollars.

17 Jun 2010

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.

17 Jun 2010

Researchers identify peptide that triggers diabetes

Researchers at National Jewish Health and the University of Colorado Anschutz Medical Campus have identified the precise protein fragment, or peptide, that can trigger diabetes in mice. The finding, published in the June 15, 2010, issue of the Proceedings of the National Academy of Sciences, supports an emerging theory about the origins of autoimmunity, and may lead to new diagnostic and therapeutic strategies in humans.

17 Jun 2010

Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome

Adi Mehta, MD stresses the growing severity of the metabolic syndrome in the May 2010 edition of Postgraduate Medicine. Metabolic syndrome often leads to cardiovascular disease (CVD) because of its key components: diabetes, dyslipidemia, and hypertension. With obesity maintaining its status as a huge problem worldwide, physicians must act as soon as possible when they recognize metabolic syndrome or any of its components.

16 Jun 2010

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

An article published in the May 2010 issue of Postgraduate Medicine highlights the seriousness of cardiovascular disease (CVD) in patients with type 2 diabetes. Cardiovascular disease is the cause of death in > 65% of patients with diabetes, and when complicated by the presence of obesity, the lifetime risk of developing CVD increases to 90%. The inherent problem is that many of the antihyperglycemic medications used to combat high glycated hemoglobin are associated with weight gain and/or hypoglycemia, which negatively affect CVD.

16 Jun 2010

A review of the response to oral anti-diabetes agents in patients with type 2 diabetes

Patients with type 2 diabetes show a progressive decline in glycemic control and receive antidiabetic therapy in order to reach the target glycated hemoglobin level of < 7% set by the American Diabetes Association and the European Association for the Study of Diabetes. An article published in the May 2010 issue of Postgraduate Medicine reviews the effectiveness of oral antidiabetes (OAD) agents in maintaining glycemic control in patients with type 2 diabetes.

16 Jun 2010

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

Type 2 diabetes is characterized by unsatisfactory levels of glycated hemoglobin (HbA1c) for extended periods. An article published in the May 2010 edition of Postgraduate Medicine reports a proposal to shorten the total time spent with uncontrolled hyperglycemia by minimizing the number of steps along the treatment-intensification ladder. In doing so, patients would decrease their exposure to hyperglycemia and potentially improve long-term outcomes.

16 Jun 2010

When doctors don't comment, parents tend to underestimate preschool children's weight: Study

Parents are more likely to underestimate their preschool children's weight when pediatricians do not tell them their children are overweight or gaining weight too fast, a study by the University of South Florida and Johns Hopkins University reports.

16 Jun 2010

Diabetes associated with increased risk of cancer

A new consensus statement of experts assembled by the American Diabetes Association and the American Cancer Society reviews emerging evidence that suggests cancer incidence is associated with diabetes as well as certain diabetes risk factors and treatments. The new report reviews the state of science concerning the association between diabetes and cancer incidence/prognosis; risk factors common to both diseases; possible biologic links between diabetes and cancer risk; and whether diabetes treatments influence the risk of cancer or cancer prognosis.

16 Jun 2010

Insulin-producing beta cells can proliferate in patients recently diagnosed with type 1 diabetes: Researchers

Researchers from the Peninsula Medical School, working in collaboration with colleagues from Glasgow Royal Infirmary and the University of Brighton, have used a unique collection of pancreas specimens taken from patients who died soon after diagnosis of type 1 diabetes to show that they respond to the ongoing process of destruction by inducing their islet cells to proliferate.

15 Jun 2010

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Artificial pancreas system reduces risk of nocturnal hypoglycemia

Gladstone Institute researcher to receive Kyoto Prize in Advanced Technology

InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting

Physical fitness reduces metabolic risk in college students

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Roche implements risk mitigation plan in taspoglutide Phase III programme

Research identifies early biomarker for insulin resistance, glucose intolerance in nondiabetic population

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

Biological mechanism associated with remission during pregnancy

Teva exercises option to invest additional $11.9M in Andromeda Biotech

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Researchers identify peptide that triggers diabetes

Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

A review of the response to oral anti-diabetes agents in patients with type 2 diabetes

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

When doctors don't comment, parents tend to underestimate preschool children's weight: Study

Diabetes associated with increased risk of cancer

Insulin-producing beta cells can proliferate in patients recently diagnosed with type 1 diabetes: Researchers

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in